Key result
Periostin promotes resistance to anti-angiogenic therapy via EMT, cell survival, and alternative angiogenesis pathways.
Why the study?
Understanding the molecular mechanisms that enable tumours to evade anti-angiogenic treatment is valuable to improve therapeutic efficacy.
Does periostin mediate tumour resistance to anti-angiogenic therapy in cancer?
Does periostin mediate tumour resistance to anti-angiogenic therapy in cancer?
Periostin is hypothesized to be a key mediator of tumor resistance to anti-angiogenic therapy, providing a potential target to improve therapeutic outcomes.
Answers are grounded in this paper and cite their sources.
Hypothesized periostin targeting may enhance anti-angiogenic efficacy; leaves open clinical validation in prospective trials.
Despite advances in the development of anti-angiogenic agents for cancer treatment, the increase in the survival duration of cancer patients is still rather modest. One major obstacle in anti-angiogenic therapy is the emergence of drug resistance. Understanding the molecular mechanisms that enable a tumour to evade anti-angiogenic treatment is valuable to improve therapeutic efficacy. Targeting blood supply usually causes hypoxic responses of tumours that trigger a series of adaptive changes leading to a resistant phenotype. Periostin, a secreted ECM (extracellular matrix) protein, is mainly produced by CAFs (cancer-associated fibroblasts) on hypoxic stress. As CAFs have been casually linked to tumour resistance to angiogenesis blockade and periostin can influence many aspects of tumour biology, we hypothesized that periostin might be a crucial mediator involved anti-angiogenic resistance in cancer treatment. This hypothesis is indirectly supported by the following facts: (a) high levels of periostin promote tumour angiogenesis; (b) periostin improves cancer cell survival under hypoxic conditions; and (c) genetic modulation of periostin induces EMT (epithelial-mesenchymal transition) and enhances cancer cell invasion and metastasis, which represents an escape mechanism from anticancer treatment. Testing and confirmation of this hypothesis will give more insight into the resistance mechanisms and provide the rationale for improvement of therapeutic outcome of anti-angiogenic therapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2011) conducted a review in Cancer. Periostin was evaluated. Periostin is hypothesized to be a crucial mediator of tumour resistance to anti-angiogenic therapy by promoting angiogenesis, improving cell survival under hypoxia, and inducing EMT.
Synapse has enriched 10 related papers. Consider them for comparative context: